Rhizen Pharma’s partnered asset Umbralisib gets US FDA accelerated nod for relapsed or refractory marginal zone lymphoma, follicular lymphoma Read more
US FDA grants Orphan Drug Designation to Zydus’ Saroglitazar for primary biliary cholangitis treatment Read more